FDA, drugmakers agree to hike fees 6%; Pfizer extends Icagen offer by 24 hours;

@FiercePharma: Serious infections in AMD patients injected off-label with Avastin. Supports Genentech case that repackaging = risky Report | Follow @FiercePharma

> The FDA and drugmakers have agreed to hike user fees by 6% over the next 5 years as part of the reauthorization of the Prescription Drug User Fee Act. News

> Pfizer ($PFE) has extended its tender offer for Icagen by 24 hours. The move is an attempt to bring in the 100,000-plus Icagen shares it needs to complete its tender offer. Story

> A Merck ($MRK) subsidiary has sued Kentucky Attorney General Jack Conway, alleging its due-process rights were violated in a Vioxx-related consumer protection case he filed in 2009. Item

> Sagent Pharmaceuticals ($SGNT) got the FDA's nod for its version of the muscle relaxant Norflex and plans to launch this quarter. Report

> Dr. Reddy's won FDA approval for its OTC version of Sanofi's ($SNY) Allegra-D 24 Hour allergy medication. Story

> GlaxoSmithKline ($GSK) bought another 600,000 of its own shares in its ongoing buyback program at prices ranging from 1,287.5 pence to 1,316.5 pence per share. Article

> Lupin Pharmaceuticals won FDA approval for its extended-release version of the Tramadol painkiller, a knockoff of Ortho-McNeil-Janssen's Ultram ER. Piece

Biotech News

@FierceBiotech: Analyst: Benlysta's shortcomings offer blockbuster opening for new lupus drugs. News | Follow @FierceBiotech

@JohnCFierce: Give the big media groups a Ph1/2 cancer drug story success and it spreads like wildfire. Diabetes, etc? Not so much. | Follow @JohnCFierce

@RyanMFierce: Just saw this report about a small EDC player called MedNet Solutions, sort of David and Goliath/Oracle story Story | Follow @RyanMFierce

> ReNeuron cleared to proceed with groundbreaking stem cell study. Article

> Cash-strapped Oxigene lays off staffers, shelves PhIII study. More

> Delcath shares slump after chemo system fails to deliver in PhII cohort. News

> Roche CEO Schwan believes diagnostics will be key to success. Report

> Beleaguered Xoma CEO Engle turns in his walking papers. Story

> Jennerex cheered by early efficacy data for cancer-killing virus. Details

Manufacturing News

> Promega adding molecular-biology capacity with new plant. More

> Fareva moves into U.S. with Pfizer plant buy. Story

> Dairy JV nabs India's excipients maker Brahmar. News

> Two CMOs to cut more than 100 jobs in NY, Ireland. Report

> BASF raises excipient, API prices another 10%. Article

> Baxter pumps up lyophilization capacity at Halle plant. Details

Vaccine News

> New strain of H5N1 lacks vax protection. News

> Emory University recieves $26M from NIH. Story

> Infant rotavirus shots may benefit the unvaccinated. Report

> IOM: Vaccines cause very few side effects. Article

> CDC: Teen HPV vaccination rates lagging. Details

And Finally... Scientists found antibiotic-resistant features in the DNA of 30,000-year-old bacteria. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.